|Day Low/High||151.75 / 156.49|
|52 Wk Low/High||29.51 / 94.01|
M&A activity should perk up substantially in the small and mid-cap space this year.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Here are Wednesday's top research calls, including upgrades for Goldman Sachs, Celanese and SBA Communications.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARCB, BCO, BOJA, CAR, CSS, DIOD, GPX, HMTA, LPL, SENEA, SVA, TGD Downgrades: EFUT, NUS, PBFX, PESI, SRDX Initiations: CXRX, IOTS, TSRO Read on to get TheStreet Quant Ratings' detailed report:
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.
U.S. stocks are higher Monday thanks to a rally in crude oil.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.
Tesaro's (TSRO) stock rating was lifted to 'buy' at Bank of America/Merrill Lynch.
Those who thought we were ready to break down look foolish again.
Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.